Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Operating Grant: Emerging COVID-19 Research Gaps and Priorities - Vaccines

University of Calgary

$434,655.00

Evaluation of COVID-19 antibodies, cell-mediated immunity and telomeres following COVID-19 immunization or natural infection in an immune compromised population: An HIV Cohort Study

FY 2021-22

Summary
Due to a critical need, vaccines against SARS-COV-2 were developed and introduced into practice in record time. This has led to a lingering uncertainty about vaccine efficacy and safety in immune compromised populations, such as persons with HIV (PWH), not specifically studied in the registration trials. There is also little data published in PWH on the immunologic response to COVID-19 infection or immunisation when stratified by age or CD4 count. As both may carry major clinical implications for poor immunity, an in-depth assessment of natural and vaccine-mediated immune response to COVID-19 in PWH is needed. We aim to assess the initial antibody response and its rate of decline and also levels of cell-mediated immunity (CMI) in PWH after COVID-19 infection or vaccination. Factors including age, sex, ethnicity, CD4 nadir, HIV viral suppression, antiretroviral therapy, co-morbidities, co-infections, vaccine type and COVID-19 variant strains will be correlated with loss of COVID-19 antibodies and markers of CMI. We will also study the association between telomere length and COVID-19 disease severity and vaccine-mediated immune response. We will use a well characterized longitudinal cohort of >2020 PWH accessing care at the Southern Alberta Clinic (SAC) and the comprehensive database that routinely collects data on the clinical and demographic factors listed above. We will identify PWH who have i) had COVID-19 infection or ii) received a COVID-19 vaccine or iii) declined immunization between 01/07/2021-01/07/2022. As routine care, bloodwork is obtained quarterly, and aliquots are stored in a biobank. Using both stored and prospective samples we will test for antibody response, markers of CMI and changes in telomere length associated with COVID-19 disease and vaccine. This will be linked to the database to stratify our analysis and evaluate confounding and effect modification. This work will assess severity of COVID-19 disease and efficacy of vaccination in PWH.
Program
Operating Grant: Emerging COVID-19 Research Gaps and Priorities - Vaccines
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
448972
Name
Gill Michael J
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Clinical
Prcname2
Operating Grant: Emerging COVID-19 Research Gaps and Priorities - Vaccines
Projecttitle
Evaluation of COVID-19 antibodies, cell-mediated immunity and telomeres following COVID-19 immunization or natural infection in an immune compromised population: An HIV Cohort Study
Programtype2
Operating Grants
Orgnameinp2
University of Calgary
Cihramount2
$434,655
Cihrequipment2
$0
Programname2
Operating Grant: Emerging COVID-19 Research Gaps and Priorities - Vaccines
Keyworddelim
Cell Mediated Immunity; Covid-19; Covid-19 Antibody Response; Covid-19 Vaccine; Immune Compromised; Natural Immunity; Persons With Hiv; Telomere Length; Vaccine-Mediated Immunity
Abstract
Due to a critical need, vaccines against SARS-COV-2 were developed and introduced into practice in record time. This has led to a lingering uncertainty about vaccine efficacy and safety in immune compromised populations, such as persons with HIV (PWH), not specifically studied in the registration trials. There is also little data published in PWH on the immunologic response to COVID-19 infection or immunisation when stratified by age or CD4 count. As both may carry major clinical implications for poor immunity, an in-depth assessment of natural and vaccine-mediated immune response to COVID-19 in PWH is needed. We aim to assess the initial antibody response and its rate of decline and also levels of cell-mediated immunity (CMI) in PWH after COVID-19 infection or vaccination. Factors including age, sex, ethnicity, CD4 nadir, HIV viral suppression, antiretroviral therapy, co-morbidities, co-infections, vaccine type and COVID-19 variant strains will be correlated with loss of COVID-19 antibodies and markers of CMI. We will also study the association between telomere length and COVID-19 disease severity and vaccine-mediated immune response. We will use a well characterized longitudinal cohort of >2020 PWH accessing care at the Southern Alberta Clinic (SAC) and the comprehensive database that routinely collects data on the clinical and demographic factors listed above. We will identify PWH who have i) had COVID-19 infection or ii) received a COVID-19 vaccine or iii) declined immunization between 01/07/2021-01/07/2022. As routine care, bloodwork is obtained quarterly, and aliquots are stored in a biobank. Using both stored and prospective samples we will test for antibody response, markers of CMI and changes in telomere length associated with COVID-19 disease and vaccine. This will be linked to the database to stratify our analysis and evaluate confounding and effect modification. This work will assess severity of COVID-19 disease and efficacy of vaccination in PWH.
Competitiondate
202104
Approvedterm2
1 yr 0 mth
Pinamesdelim
Gill, Michael J; Hu, Jia; McMillan, Jacqueline M; Power, Christopher; Riabowol, Karl T
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $434,655~ $0~
University of Calgary - $434,655 Grant (2021-22) | Canada Spends